As we enter, what can only be described as critical, these next...

As we enter, what can only be described as critical, these next two weeks I thought it appropriate to outline the key dates for POH moving forward. I will give Ross and the management team this that they have supplied as with a lot of information to process over the last six months. The AGM seemed to crystallise a few of these dates for me. By looking at some of the earlier updates I am hoping to paint the picture of what POH could look like coming into march next year (when the current cash will run out).
Week of June 4^th – Mylan Arbitration Update
July – August 2018 – Potential Roden-Fields announcement. At about this time Roden-Fields would have had 8-9 months of developing mixtures as the started developing in December 2017.  Hottod mentioned in discussions with Ross that these were progressing well. I am not sure how long it would take however given it takes 2 years for a injectable surely these mixtures must be less than a year.
August 2018– The next injectable candidate should be announced. In the march newsletter it was outlined that Daptomycin is in late phase development, the second Propofol is progressing then the newsletter mentions a third (or possible multiple) unnamed leads with expectations for the 2^nd half of 2018. The list was pretty extensive including Clopidogrel, Tacrolimus, Vitamin K, Azithromycin etc.
September 2018– FDA feedback on patches is expected by the end of the third quarter. Potentially very significant, could either revive the patches or this could be it for patches. If positive I suspect a partnership to be announced fairly quickly thereafter. Ross has mentioned that POH has had numerous discussions with potential partners.
October 2018– Propofol announcement of POC clinical trials (Ross mentioned that Terumo is already in the toxicology stage with Propofol. On the 9/11/17 the announcement stated that the research collaboration had been in play for 15 months indicating the formulation stability stage. They indicated that animal studies conducted by Terumo would begin in 2017 and extend into 2018. This means that these studies have been undertaken for about 8 months (November to June). Given this stage usually last 12 months we can expect an announcement sometime in October.
December 2018 – From the AGM POH expect potential agreement with feed companies to have occurred by the end of December 2018 or early 2019
October to December 2018 - Biolexar –  Again thanks to Hottod we know that Pure Beauty is having some trouble with formulations and we also know that Ross has been assured that they are still interested in bringing it market.
March 2019 – Further Cash Raise as money will be low without significant improvement, major announcement or Mylan Payout.
November 2019 – Propofol - RM mentioned in the AGM that it normally takes 2 years from stability to product being ready for market. Given we know the toxicology started in November 2017 we can expect the product coming to market in November 2019 (if we are still in existence!)